Achaemenid dynasty

Atossa Therapeutics To Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on September 22, 2020

Retrieved on: 
Monday, September 21, 2020
Life sciences, Articles, Biotechnology, Achaemenid dynasty, Atossa, Biopharmaceutical

The company is presenting at 9:10 AM ET on September 22nd.

Key Points: 
  • The company is presenting at 9:10 AM ET on September 22nd.
  • For those interested in participating in the conference, please email [email protected] to obtain the link.
  • Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19.
  • For more information, please visit www.atossatherapeutics.com.

Atossa Therapeutics to Present at the LD Micro 500 Virtual Conference on September 4, 2020

Retrieved on: 
Wednesday, August 26, 2020
Achaemenid dynasty, Atossa

In addition, Dr. Quay will be available for virtual one-on-one meetings from September 1-4, 2020.

Key Points: 
  • In addition, Dr. Quay will be available for virtual one-on-one meetings from September 1-4, 2020.
  • To schedule a meeting please contact Eric Lahiji at [email protected].
  • Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19.
  • For more information, please visit www.atossatherapeutics.com.

Atossa Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 13, 2020
Health, Achaemenid dynasty, Atossa, Clinical trial, Articles

As of August 3, 2020, all necessary approvals were obtained and enrollment is expected to begin in the coming weeks.

Key Points: 
  • As of August 3, 2020, all necessary approvals were obtained and enrollment is expected to begin in the coming weeks.
  • Avance is a leading Australian clinical research organization and has successfully completed multiple clinical studies of Atossas proprietary Endoxifen.
  • Completed sales of all available shares under Atossas at-the-market financing program with total gross proceeds to Atossa of $5 million through July 2020.
  • For the quarter ended June 30, 2020, Atossa had no source of sustainable revenue and no associated cost of revenue.

Atossa Therapeutics Announces First Quarter 2020 Financial Results and Provides Company Update on COVID-19 HOPE and Endoxifen Programs

Retrieved on: 
Wednesday, May 13, 2020
Health, RTT, Achaemenid dynasty, Atossa, Clinical trial, Breast cancer, Atossa Genetics

Atossa has applied to the FDA for approval to commence a clinical study in this setting.

Key Points: 
  • Atossa has applied to the FDA for approval to commence a clinical study in this setting.
  • Announced that Atossa has contracted with NYC Health + Hospitals/Metropolitan in New York City to conduct the COVID-19 HOPE study of AT-H201.
  • Announced positive interim results from Atossas Phase 2 study of oral Endoxifen to treat breast cancer in the window of opportunity between diagnosis of breast cancer and surgery.
  • For the quarter ended March 31, 2020, Atossa had no source of sustainable revenue and no associated cost of revenue.

Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2020

Retrieved on: 
Wednesday, January 22, 2020
Achaemenid dynasty, Atossa, Atossa Genetics

SEATTLE, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS) today issued the following letter from Dr. Steven C. Quay, President and CEO, to Atossa shareholders:

Key Points: 
  • SEATTLE, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS) today issued the following letter from Dr. Steven C. Quay, President and CEO, to Atossa shareholders:
    I begin this letter with a sense of great pride about our accomplishments at Atossa.
  • We advanced our goal of developing our intraductal microcatheter technology to deliver drugs and immunotherapies to treat breast cancer.
  • We look forward to reporting our progress on our priorities throughout the year and we thank you for your continued support of Atossa.
  • Atossa Therapeutics, Inc. (Nasdaq:ATOS) is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.